The most common side effect noted was a non-CTCL pruritic rash consistent with MAR, which, in our patients, appeared to correlate with disease control. Our data support the need for additional ...

Pembrolizumab demonstrated clinical activity in patients with mycosis fungoides (MF) and Sézary syndrome (SS), the most common subtypes of cutaneous T-cell lymphoma (CTCL), with nearly half of ...

The BTD is granted based on phase 1 study results as well as results from the phase 2 TELLOMAK study, where lacutamab demonstrated encouraging efficacy and a favourable safety profile in heavily ...

“There is a high unmet medical need for patients with Sézary syndrome. In this aggressive and rare form of cutaneous T-cell lymphoma, patients in advanced disease often experience very poor ...

Resminostat is under clinical development by 4SC and currently in Phase II for Sezary Syndrome. According to GlobalData, Phase II drugs for Sezary Syndrome have a 38% phase transition success rate ...

POTELIGEO injection for intravenous infusion is indicated for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior ...

Sezary syndrome is an erythrodermic cutaneous T-cell lymphoma with the leukemic component. Erythroderma is an intense, widespread, pruritic, exfoliative rash representing new lesions or progression of ...

A lymphoma rash can appear as one or more scaly patches ... In some cases of MF or Sezary syndrome, a doctor may recommend a bone marrow transplant. Surgery is not a common treatment for cutaneous ...

1 Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States 2 Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, ...